Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MB-CART 19.1 by Miltenyi Biomedicine for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
MB-CART 19.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL)....
MB-CART 19.1 by Miltenyi Biomedicine for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
MB-CART 19.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL)....
MB-CART 19.1 by Miltenyi Biomedicine for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
MB-CART 19.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to...
MB-CART 19.1 by Miltenyi Biomedicine for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
MB-CART 19.1 is under clinical development by Miltenyi Biomedicine and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute...
Zamtocabtagene autoleucel by Miltenyi Biomedicine for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to...
Zamtocabtagene autoleucel by Miltenyi Biomedicine for Follicular Lymphoma: Likelihood of Approval
Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for Follicular Lymphoma. According to GlobalData,...
Zamtocabtagene autoleucel by Miltenyi Biomedicine for Mantle Cell Lymphoma: Likelihood of Approval
Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for Mantle Cell Lymphoma. According to...
Zamtocabtagene autoleucel by Miltenyi Biomedicine for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...
Zamtocabtagene autoleucel by Miltenyi Biomedicine for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...
CAR20.19.22 T-cells by Miltenyi Biomedicine for Marginal Zone B-cell Lymphoma: Likelihood of Approval
CAR20.19.22 T-cells is under clinical development by Miltenyi Biomedicine and currently in Phase I for Marginal Zone B-cell Lymphoma. According...
CAR20.19.22 T-cells by Miltenyi Biomedicine for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
CAR20.19.22 T-cells is under clinical development by Miltenyi Biomedicine and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According...
CAR20.19.22 T-cells by Miltenyi Biomedicine for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
CAR20.19.22 T-cells is under clinical development by Miltenyi Biomedicine and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to...
CAR20.19.22 T-cells by Miltenyi Biomedicine for Follicular Lymphoma: Likelihood of Approval
CAR20.19.22 T-cells is under clinical development by Miltenyi Biomedicine and currently in Phase I for Follicular Lymphoma. According to GlobalData,...
CAR20.19.22 T-cells by Miltenyi Biomedicine for Burkitt Lymphoma: Likelihood of Approval
CAR20.19.22 T-cells is under clinical development by Miltenyi Biomedicine and currently in Phase I for Burkitt Lymphoma. According to GlobalData,...
CAR20.19.22 T-cells by Miltenyi Biomedicine for Mantle Cell Lymphoma: Likelihood of Approval
CAR20.19.22 T-cells is under clinical development by Miltenyi Biomedicine and currently in Phase I for Mantle Cell Lymphoma. According to...
CAR20.19.22 T-cells by Miltenyi Biomedicine for T-Cell Lymphomas: Likelihood of Approval
CAR20.19.22 T-cells is under clinical development by Miltenyi Biomedicine and currently in Phase I for T-Cell Lymphomas. According to GlobalData,...
CAR20.19.22 T-cells by Miltenyi Biomedicine for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
CAR20.19.22 T-cells is under clinical development by Miltenyi Biomedicine and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According...
Zamtocabtagene autoleucel by Miltenyi Biomedicine for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Zamtocabtagene autoleucel is under clinical development by Miltenyi Biomedicine and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According...